Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81641 | 0.83 | DRD2 (0.54) | DRD2SLC18A3HRH3SLC6A4CARM1 | |
| SCHEMBL1002870 | 0.81 | DRD2 (0.53) | DRD2SLC18A3HRH3SLC6A4CARM1 | |
| SCHEMBL6249416 | 0.81 | DRD2 (0.53) | DRD2SLC18A3HRH3SLC6A4CARM1 | |
| SCHEMBL10287616 | 0.81 | DRD2 (0.77) | DRD2SLC18A3DRD3 | |
| SCHEMBL11440535 | 0.81 | DRD2 (0.53) | DRD2SLC18A3HRH3SLC6A4CARM1 | |
| SCHEMBL1812772 | 0.81 | GAA (0.53) | DRD2SLC18A3HRH3SLC6A4CARM1 | |
| SCHEMBL6991321 | 0.81 | DRD2 (0.53) | DRD2SLC18A3DRD3 | |
| SCHEMBL1003503 | 0.81 | DRD2 (0.73) | DRD2SLC18A3CARM1PRMT6DRD3 | |
| SCHEMBL1751658 | 0.81 | DRD2 (0.61) | DRD2DRD3 | |
| SCHEMBL23367743 | 0.79 | HRH3 (0.60) | DRD2HRH3DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | claimed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | claimed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | claimed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| EP-2512476-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | Novartis AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120258940-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2011075620-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258940-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | FGFR3, FGFR2, FGFR1 | DRD2 4771/4885SLC18A3 4480/4885HRH3 432/4885 |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | DRD2 4822/4885SLC18A3 4758/4885HRH3 1854/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | DRD2 4822/4885SLC18A3 4758/4885HRH3 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.